Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Q: How can investors meet Bone Biologics (BBLG) management at the H.C. Wainwright conference?

CEO Jeff Frelick will hold one-on-one meetings with investors from September 14–16, 2026. Investors can request meetings by registering for the conference through the event website.

Bone Biologics (BBLG) will participate in the H.C.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Bone Biologics (BBLG) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14–16, 2026. CEO Jeff Frelick will hold one-on-one investor meetings during the event. A virtual corporate presentation will be available on-demand from September 11, 2026 at 7:00 AM ET for registered attendees via the conference platform.

Argus Sep 3 session 1 alert

+1.38% close to close 2.3x rel. volume Open Argus

Details

News Market Reaction – BBLG

$1.59M Mkt Cap at Peak Alert

On Sep 3, the day this news came out, BBLG closed 1.38% above the previous close. Relative volume reached 2.3x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Conference edition: 28th annual Conference dates: September 14–16, 2026 Investor meetings: September 14–16 +1 more

Conference edition: 28th annual; H.C. Wainwright Global Investment Conference
Conference dates: September 14–16, 2026; Lotte New York Palace Hotel
Investor meetings: September 14–16; One-on-one meetings with investors
Presentation availability: September 11 at 7:00 AM ET; Virtual presentation available on-demand

Historical Context

4 past events · Latest: Aug 12

4 events

Aug 12
Shelf-life milestone

24h Move

-28.6%

Validated rhNELL-1 shelf life extended to 32 months with third-party stability data.
Jul 23
Shareholder update

24h Move

-1.8%

Update covered financing, clinical progress, manufacturing readiness, and runway through Q2 2027.
Jul 07
Private placement

24h Move

-8.8%

Private placement raised approximately $3.0 million upfront with additional warrant proceeds possible.
May 19
Shelf-life milestone

24h Move

+0.8%

Validated rhNELL-1 shelf life extended to 29 months from 24 months.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

orthobiologic, preclinical research, bone graft substitute, spine fusion

4 terms

orthobiologic medical

"a developer of orthobiologic products for spine fusion markets"

Orthobiologics are medical products made from natural substances—such as blood, bone, or growth factors—used to help heal bones, joints and soft tissues faster or more effectively. For investors, they matter because they represent a growing segment of healthcare that can offer less invasive, often outpatient treatments with potential for recurring sales, intellectual property, and reimbursement shifts that can affect revenue and valuation in companies developing or commercializing these therapies.

preclinical research medical

"builds on the preclinical research of the NELL-1 protein"

Preclinical research is the stage of drug or medical-device development where scientists test a candidate in the lab and in animals to assess safety, dosing and whether it works before giving it to humans. For investors, this phase is like a prototype being tested in a workshop: positive preclinical results reduce the unknowns and can increase a project’s value, while failures or unclear data signal higher risk and longer timelines to any potential return.

bone graft substitute medical

"development efforts for its bone graft substitute product"

A bone graft substitute is a medical device or material used to replace, augment, or support a patient’s own bone when natural bone is missing, damaged, or needs help healing. It matters to investors because these products are regulated medical technologies sold to hospitals and surgeons, and their safety, effectiveness, regulatory approvals, and market adoption determine clinical use, reimbursement, and revenue potential—think of them as engineered scaffolds that help the body rebuild bone.

spine fusion medical

"bone regeneration in spinal fusion procedures"

Spine fusion is a surgical procedure that joins two or more bones in the spine so they heal into a single, stable unit—think of it as welding together loose links in a chain to stop unwanted movement. Investors care because the procedure drives sales of implants, surgical tools, hospital services, and post-op care; changes in demand, reimbursement rules, or new technologies can affect manufacturers, healthcare providers, and insurers’ revenues and costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/03/2026 - 08:30 AM EDT

BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28^th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Jeff Frelick, Chief Executive Officer of Bone Biologics will hold one-on-one meetings with investors on September 14 – 16. A virtual presentation will be available on-demand starting Friday, September 11 at 7:00 AM ET. The presentation will be available for registered attendees via the conference platform.

To request a meeting and to register for the conference: https://hcwevents.com/annualconference/.

About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Contacts
CORE IR
(212) 655-0924
investors@bonebiologics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bone Biologics (BBLG) attend the H.C. Wainwright 28th Annual Global Investment Conference?

Bone Biologics will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14–16, 2026. The event will take place at the Lotte New York Palace Hotel in New York.

How can investors meet Bone Biologics (BBLG) management at the H.C. Wainwright conference?

CEO Jeff Frelick will hold one-on-one meetings with investors from September 14–16, 2026. Investors can request meetings by registering for the conference through the event website.

How can I watch Bone Biologics (BBLG) virtual presentation from the H.C. Wainwright conference?

A Bone Biologics virtual presentation will be available on-demand starting Friday, September 11, 2026 at 7:00 AM ET. Registered conference attendees can access it via the conference’s online platform.

Where can investors register to see Bone Biologics (BBLG) at the H.C. Wainwright 2026 conference?

Investors can register and request a meeting with Bone Biologics by visiting https://hcwevents.com/annualconference/. Registration provides access to the conference platform and the company’s on-demand presentation.

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference